Impact of Pharmacogenetics on High-Dose Methotrexate Toxicity in Pediatric Oncology.

ABSTRACT: Background: Childhood cancers represent a heterogeneous group of malignancies and remain one of the leading causes of mortality among children under 14 years of age, ranking second only to accidental injuries, and fourth among individuals aged 15 to 19 years. Despite notable improvements in cure rates, a substantial proportion of patients experience acute or long-term toxicities associated with treatment. Methotrexate (MTX), a chemotherapeutic agent, has been employed effectively for over six decades in the management of pediatric malignancies. High-dose methotrexate constitutes a cornerstone of pediatric cancer therapy; however, its clinical utility is frequently constrained by dose-limiting toxicities. Objectives: This study investigates the impact of genetic polymorphisms

SUBMITTER: Marangoni-Iglecias LM 

PROVIDER: S-EPMC12115323 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature